Burlington, Canada
EmpowerPharm, founded in 2018, is a Canadian biotechnology startup making strides with its pioneering venture: the world’s first prescription pharmaceutical-grade CBD tablet. With its main focus on developing treatments for anxiety sufferers, EmpowerPharm is committed to advancing the therapeutic applications of CBD under stringent pharmaceutical guidelines.
The company brings an impressive team onboard, comprised of experienced healthcare and pharmaceutical professionals with over 450 years of cumulative industry expertise. Although currently an early-stage enterprise, its innovative approaches and the significant market potential within the CBD pharmaceutical landscape position it as an attractive prospect for potential investors.
Operating primarily within the Biotechnology sector, EmpowerPharm has not yet received recorded outside investment but stands as a promising opportunity, demonstrating a unique integration of medicinal cannabis with mainstream pharmaceutical protocols. Headquartered in Canada, the company is at the forefront of a growing niche that combines biotech innovation with mental health solutions.
